130 related articles for article (PubMed ID: 7281240)
21. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
Jacquillat C; Banzet P; Civatte J; Puissant A; Cottenot F; Israel L; Belaich S; Chastang C; Maral J
Recent Results Cancer Res; 1978; 68():346-58. PubMed ID: 111323
[No Abstract] [Full Text] [Related]
23. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
24. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.
Webb HE; Oaten SW; Pike CP
Br Med J; 1978 Feb; 1(6109):338-40. PubMed ID: 623981
[TBL] [Abstract][Full Text] [Related]
25. Nephrotoxicity from cancer immunotherapy.
Dosik GM; Gutterman JU; Hersh EM; Akhtar M; Sonoda T; Horn RG
Ann Intern Med; 1978 Jul; 89(1):41-6. PubMed ID: 666183
[TBL] [Abstract][Full Text] [Related]
26. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
27. Surgical adjuvant therapy for malignant melanoma.
Pinsky CM; Oettgen HF
Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
[No Abstract] [Full Text] [Related]
28. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
29. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum.
MacEwen EG; Patnaik AK; Harvey HJ; Hayes AA; Matus R
Cancer Invest; 1986; 4(5):397-402. PubMed ID: 3801954
[TBL] [Abstract][Full Text] [Related]
30. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
[TBL] [Abstract][Full Text] [Related]
31. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M; Caubet JF; McGarry R
Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
[TBL] [Abstract][Full Text] [Related]
32. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
33. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
34. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
Thatcher N; Blackledge G; Palmer MK; Crowther D
Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256
[No Abstract] [Full Text] [Related]
35. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
Kogoniia LM; Moroz LV; Perevodchikova NI; Platinskiĭ LV; Borisov AI
Vopr Onkol; 1981; 27(4):16-21. PubMed ID: 7015692
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy from malignant disease.
Goodnight JE; Morton DL
Annu Rev Med; 1978; 29():231-83. PubMed ID: 348035
[No Abstract] [Full Text] [Related]
38. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
39. Regression of regionally advanced melanoma after arterial infusion with cis-platinum and actinomycin-D.
Pritchard JD; Mavligit GM; Wallace S; Benjamin RS; McBride CM
Clin Oncol; 1979 Jun; 5(2):179-82. PubMed ID: 466896
[No Abstract] [Full Text] [Related]
40. Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man.
Cederholm-Williams SA; King A; Allington MJ; Gill PG; Sharp AA; Britton BJ
Br J Cancer; 1978 Jun; 37(6):1074-7. PubMed ID: 678428
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
